1. Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial.
- Author
-
Eshleman SH, Hudelson SE, Redd AD, Swanstrom R, Ou SS, Zhang XC, Ping LH, Piwowar-Manning E, Porcella SF, Sievers MF, Martens CA, Bruno D, Dukhovlinova E, McCauley M, Gamble T, Fogel JM, Sabin D, Quinn TC, Gunde L, Maliwichi M, Nhando N, Akelo V, Moyo S, Panchia R, Kumarasamy N, Chotirosniramit N, Melo MG, Pilotto J, Grinsztejn B, Mayer K, Chen YQ, Hughes JP, and Cohen MS
- Subjects
- Cohort Studies, Female, Humans, Male, Treatment Outcome, Anti-HIV Agents administration & dosage, Chemoprevention methods, Disease Transmission, Infectious prevention & control, HIV Infections prevention & control
- Abstract
HIV Prevention Trials Network 052 demonstrated that antiretroviral therapy (ART) prevents HIV transmission in serodiscordant couples. HIV from index-partner pairs was analyzed to determine the genetic linkage status of partner infections. Forty-six infections were classified as linked, indicating that the index was the likely source of the partner's infection. Lack of viral suppression and higher index viral load were associated with linked infection. Eight linked infections were diagnosed after the index started ART: 4 near the time of ART initiation and 4 after ART failure. Linked infections were not observed when the index participant was stably suppressed on ART., Competing Interests: Conflict of Interests None of the authors has a financial or personal relationship with other people or organizations that could inappropriately influence (bias) their work. The following relationship is noted: SHE has collaborated with Abbott Diagnostics (distributor of the ViroSeq HIV Genotyping System) on evaluation of HIV-related assays.
- Published
- 2017
- Full Text
- View/download PDF